Circulating Cytotoxic T Lymphocytes Associated Antigen-4 (CTLA-4) Levels and CTLA-4 Gene Polymorphism Role in Head and Neck Squamous Cell Carcinoma
1
Department of Microbiology, College of Medicine, University of Diyala, Diyala, Iraq, Iraq
2
Department of Microbiology, College of Medicine, Tikrit University, Tikrit, Iraq, Iraq
3
College of Pharmacy, University of Al Maarif, College of Pharmacy, University of Al Maarif, Al Anbar, 31001, Iraq, Iraq
4
Al-Amal National Hospital, Baghdad City Complex, Ministry of Health Environment, Baghdad, Iraq, Iraq
5
Department of Radiation Oncology, Baghdad Radiation Oncology and Nuclear Medicine Center, Baghdad Medical City Complex, Ministry of Health environment, Baghdad, Iraq, Iraq
Submission date: 2025-06-01
Acceptance date: 2025-11-23
Publication date: 2025-12-30
Corresponding author
Hiba Hadi Rashid
Department of Microbiology, College of Medicine, University of Diyala, Diyala, Iraq, Iraq
Department of Microbiology, College of Medicine, University of Diyala, Diyala, Iraq, Iraq
Wiadomości Lekarskie 2025;(12):2586-2593
KEYWORDS
TOPICS
ABSTRACT
Aim:
Aim: To determine the function of soluble CTLA-4 and the CTLA-4+49A/G gene polymorphism in patients with head and neck squamous cell carcinoma.
Material and methods:
Materials and Methods: The current study recruited 180 subjects (90 patients with HNSCCs and comparable number apparently healthful persons as reference) from February 2024 to February 2025.These subjects selected from Medical City, Baghdad, Iraq. All individuals' genomic DNA was extracted from blood samples. To evaluate soluble (sCTLA-4), an enzyme-linked immunoassay kit was used. The Tetra-Primer Amplification Refractory System-Polymerase Chain Reaction (T-ARMS-PCR) was used to genotype and amplification of the CTLA-4 gene using specific primers.
Results:
Results: As opposed to controls (median = 389.5 ng/ml, range = 160-1966 ng/ml), the median serum level of sCTLA-4 in patients was 1593.5 ng/ml (range = 1118-2000 ng/ml), which was noticeably higher. There was a significant difference (p=0.024) in the frequency of patients with the AA genotype compared to those did not (67.78% vs. 50%). Conversely, controls had a significantly higher frequency of the heterozygous genotype (AG) than patients (37.78% vs. 28.89%) (OR= 0.20, 95%CI=0.05-0.76, p=0.018). At allelic level, G allele was far more frequent in controls than patients (31.11% versus 17.78%).
Conclusions:
Conclusion: The G allele and the heterozygous genotype (AG) may be regarded as protective factors from HNSCC, and AA genotype is risk factor for HNSCC. Soluble CTLA-4 rise remarkably in patients with HNSCC suggesting a function for this protein in pathogenesis of this disease.
Aim: To determine the function of soluble CTLA-4 and the CTLA-4+49A/G gene polymorphism in patients with head and neck squamous cell carcinoma.
Material and methods:
Materials and Methods: The current study recruited 180 subjects (90 patients with HNSCCs and comparable number apparently healthful persons as reference) from February 2024 to February 2025.These subjects selected from Medical City, Baghdad, Iraq. All individuals' genomic DNA was extracted from blood samples. To evaluate soluble (sCTLA-4), an enzyme-linked immunoassay kit was used. The Tetra-Primer Amplification Refractory System-Polymerase Chain Reaction (T-ARMS-PCR) was used to genotype and amplification of the CTLA-4 gene using specific primers.
Results:
Results: As opposed to controls (median = 389.5 ng/ml, range = 160-1966 ng/ml), the median serum level of sCTLA-4 in patients was 1593.5 ng/ml (range = 1118-2000 ng/ml), which was noticeably higher. There was a significant difference (p=0.024) in the frequency of patients with the AA genotype compared to those did not (67.78% vs. 50%). Conversely, controls had a significantly higher frequency of the heterozygous genotype (AG) than patients (37.78% vs. 28.89%) (OR= 0.20, 95%CI=0.05-0.76, p=0.018). At allelic level, G allele was far more frequent in controls than patients (31.11% versus 17.78%).
Conclusions:
Conclusion: The G allele and the heterozygous genotype (AG) may be regarded as protective factors from HNSCC, and AA genotype is risk factor for HNSCC. Soluble CTLA-4 rise remarkably in patients with HNSCC suggesting a function for this protein in pathogenesis of this disease.
Share
RELATED ARTICLE
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
